SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials Read more about SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results Read more about SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech Read more about SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022 Read more about SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022 SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat Read more about SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat SIGA Announces Health Canada Regulatory Approval of Oral TPOXX® Read more about SIGA Announces Health Canada Regulatory Approval of Oral TPOXX® European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat Read more about European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021 Read more about SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021 SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results Read more about SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX® Read more about SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX® Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to
SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials Read more about SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials
SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results Read more about SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results
SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech Read more about SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech
SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022 Read more about SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat Read more about SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat
SIGA Announces Health Canada Regulatory Approval of Oral TPOXX® Read more about SIGA Announces Health Canada Regulatory Approval of Oral TPOXX®
European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat Read more about European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat
SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021 Read more about SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021
SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results Read more about SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results
SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX® Read more about SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX®